Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.

Churchman ML, Low J, Qu C, Paietta EM, Kasper LH, Chang Y, Payne-Turner D, Althoff MJ, Song G, Chen SC, Ma J, Rusch M, McGoldrick D, Edmonson M, Gupta P, Wang YD, Caufield W, Freeman B, Li L, Panetta JC, Baker S, Yang YL, Roberts KG, McCastlain K, Iacobucci I, Peters JL, Centonze VE, Notta F, Dobson SM, Zandi S, Dick JE, Janke L, Peng J, Kodali K, Pagala V, Min J, Mayasundari A, Williams RT, Willman CL, Rowe J, Luger S, Dickins RA, Guy RK, Chen T, Mullighan CG.

Cancer Cell. 2015 Sep 14;28(3):343-56. doi: 10.1016/j.ccell.2015.07.016. Epub 2015 Aug 27.

2.

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML.

Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23.

3.

Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.

Cazzaniga G, van Delft FW, Lo Nigro L, Ford AM, Score J, Iacobucci I, Mirabile E, Taj M, Colman SM, Biondi A, Greaves M.

Blood. 2011 Nov 17;118(20):5559-64. doi: 10.1182/blood-2011-07-366542. Epub 2011 Sep 29.

4.

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR.

Nature. 2008 May 1;453(7191):110-4. doi: 10.1038/nature06866. Epub 2008 Apr 13.

PMID:
18408710
5.

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).

Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, Astolfi A, Chiaretti S, Vitale A, Messa F, Impera L, Baldazzi C, D'Addabbo P, Papayannidis C, Lonoce A, Colarossi S, Vignetti M, Piccaluga PP, Paolini S, Russo D, Pane F, Saglio G, Baccarani M, Foà R, Martinelli G.

Blood. 2009 Sep 3;114(10):2159-67. doi: 10.1182/blood-2008-08-173963. Epub 2009 Jul 9. Erratum in: Blood. 2010 Sep 23;116(12):2196.

6.

Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia.

Churchman ML, Mullighan CG.

Exp Hematol. 2017 Feb;46:1-8. doi: 10.1016/j.exphem.2016.11.002. Epub 2016 Nov 16. Review.

7.

Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.

Vitanza NA, Zaky W, Blum R, Meyer JA, Wang J, Bhatla T, Morrison DJ, Raetz EA, Carroll WL.

Pediatr Blood Cancer. 2014 Oct;61(10):1779-85. doi: 10.1002/pbc.25119. Epub 2014 Jun 29.

8.

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.

Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, Soverini S, Vitale A, Chiaretti S, Cimino G, Papayannidis C, Paolini S, Elia L, Fazi P, Meloni G, Amadori S, Saglio G, Pane F, Baccarani M, Foà R.

J Clin Oncol. 2009 Nov 1;27(31):5202-7. doi: 10.1200/JCO.2008.21.6408. Epub 2009 Sep 21.

PMID:
19770381
9.

Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.

Yao QM, Liu KY, Gale RP, Jiang B, Liu YR, Jiang Q, Jiang H, Zhang XH, Zhang MJ, Chen SS, Huang XJ, Xu LP, Ruan GR.

BMC Cancer. 2016 Apr 11;16:269. doi: 10.1186/s12885-016-2300-7.

10.

Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.

Kobitzsch B, Gökbuget N, Schwartz S, Reinhardt R, Brüggemann M, Viardot A, Wäsch R, Starck M, Thiel E, Hoelzer D, Burmeister T.

Haematologica. 2017 Oct;102(10):1739-1747. doi: 10.3324/haematol.2016.161273. Epub 2017 Jul 27.

11.

IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.

van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ, Cavé H, Trka J, Saha V, Schrappe M, Pieters R, Biondi A, Valsecchi MG, Stanulla M, den Boer ML, Cazzaniga G.

Blood. 2014 Mar 13;123(11):1691-8. doi: 10.1182/blood-2013-06-509794. Epub 2013 Dec 23.

12.

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.

Boer JM, Steeghs EM, Marchante JR, Boeree A, Beaudoin JJ, Beverloo HB, Kuiper RP, Escherich G, van der Velden VH, van der Schoot CE, de Groot-Kruseman HA, Pieters R, den Boer ML.

Oncotarget. 2017 Jan 17;8(3):4618-4628. doi: 10.18632/oncotarget.13492.

13.

Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.

Volejnikova J, Mejstrikova E, Dörge P, Meissner B, Zimmermannova O, Svojgr K, Stanulla M, Cario G, Schrappe M, Stary J, Hrusak O, Trka J, Fronkova E.

Pediatr Blood Cancer. 2013 Mar;60(3):420-7. doi: 10.1002/pbc.24299. Epub 2012 Sep 19.

PMID:
22997141
14.

Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.

Dong Y, Liu F, Wu C, Li S, Zhao X, Zhang P, Jiao J, Yu X, Ji Y, Zhang M.

Clin Exp Immunol. 2016 Sep;185(3):320-31. doi: 10.1111/cei.12812. Epub 2016 Jul 28.

15.

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.

Hovorkova L, Zaliova M, Venn NC, Bleckmann K, Trkova M, Potuckova E, Vaskova M, Linhartova J, Machova Polakova K, Fronkova E, Muskovic W, Giles JE, Shaw PJ, Cario G, Sutton R, Stary J, Trka J, Zuna J.

Blood. 2017 May 18;129(20):2771-2781. doi: 10.1182/blood-2016-11-749978. Epub 2017 Mar 22.

16.

The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia.

Marke R, van Leeuwen FN, Scheijen B.

Haematologica. 2018 Apr;103(4):565-574. doi: 10.3324/haematol.2017.185603. Epub 2018 Mar 8. Review.

17.

Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.

DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock W.

Leuk Lymphoma. 2016 Oct;57(10):2298-306. doi: 10.3109/10428194.2016.1144881. Epub 2016 Feb 18.

18.

IKAROS isoform 6 enhances BCR-ABL1-mediated proliferation of human CD34+ hematopoietic cells on stromal cells.

Suzuki K, Ono R, Ohishi K, Masuya M, Kataoka I, Liu B, Nakamori Y, Ino K, Monma F, Hamada H, Kitamura T, Katayama N, Nosaka T.

Int J Oncol. 2012 Jan;40(1):53-62. doi: 10.3892/ijo.2011.1192. Epub 2011 Sep 7.

PMID:
21901249
19.

IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia.

Yamashita Y, Shimada A, Yamada T, Yamaji K, Hori T, Tsurusawa M, Watanabe A, Kikuta A, Asami K, Saito AM, Horibe K.

Pediatr Blood Cancer. 2013 Oct;60(10):1587-92. doi: 10.1002/pbc.24571. Epub 2013 Jun 27.

PMID:
23804397
20.

Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.

Bond J, Domaschenz R, Roman-Trufero M, Sabbattini P, Ferreiros-Vidal I, Gerrard G, Asnafi V, Macintyre E, Merkenschlager M, Dillon N.

Oncotarget. 2016 Oct 4;7(40):65923-65936. doi: 10.18632/oncotarget.11688.

Supplemental Content

Support Center